Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell, Cutaneous | 7 | 2023 | 294 | 2.250 |
Why?
|
| Mycosis Fungoides | 9 | 2024 | 320 | 2.030 |
Why?
|
| Sezary Syndrome | 5 | 2023 | 159 | 1.720 |
Why?
|
| Skin Neoplasms | 17 | 2024 | 4654 | 1.580 |
Why?
|
| Drug Eruptions | 4 | 2020 | 256 | 1.020 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 32 | 0.740 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2019 | 9 | 0.730 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2019 | 53 | 0.700 |
Why?
|
| Sarcoma, Kaposi | 1 | 2020 | 187 | 0.640 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 308 | 0.570 |
Why?
|
| Dermatomyositis | 1 | 2015 | 34 | 0.540 |
Why?
|
| Epidermal Cyst | 1 | 2015 | 46 | 0.530 |
Why?
|
| Retinoids | 1 | 2015 | 164 | 0.500 |
Why?
|
| Skin Diseases | 3 | 2021 | 349 | 0.450 |
Why?
|
| Toll-Like Receptors | 1 | 2014 | 174 | 0.440 |
Why?
|
| Calcinosis | 1 | 2015 | 423 | 0.420 |
Why?
|
| Pemphigoid, Bullous | 2 | 2022 | 24 | 0.400 |
Why?
|
| Immunologic Factors | 1 | 2015 | 649 | 0.400 |
Why?
|
| Lymphomatoid Papulosis | 2 | 2021 | 68 | 0.340 |
Why?
|
| Exanthema | 2 | 2020 | 211 | 0.320 |
Why?
|
| Lichenoid Eruptions | 2 | 2019 | 36 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2992 | 0.290 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2005 | 33 | 0.250 |
Why?
|
| Allopurinol | 1 | 2005 | 54 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 5437 | 0.240 |
Why?
|
| Skin | 3 | 2021 | 1259 | 0.240 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2022 | 20 | 0.210 |
Why?
|
| Photochemotherapy | 1 | 2022 | 96 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2024 | 181 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 3251 | 0.210 |
Why?
|
| Antigens, CD7 | 1 | 2020 | 23 | 0.190 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 361 | 0.190 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 54 | 0.190 |
Why?
|
| GATA3 Transcription Factor | 1 | 2021 | 146 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 171 | 0.180 |
Why?
|
| Humans | 33 | 2024 | 261506 | 0.180 |
Why?
|
| Ki-1 Antigen | 1 | 2021 | 182 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 4744 | 0.180 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 147 | 0.170 |
Why?
|
| Keratitis, Herpetic | 1 | 2019 | 28 | 0.170 |
Why?
|
| Coccidioidomycosis | 1 | 2018 | 32 | 0.160 |
Why?
|
| Aged | 13 | 2021 | 70117 | 0.150 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 259 | 0.140 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2016 | 25 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 387 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 1678 | 0.140 |
Why?
|
| Quality of Life | 2 | 2020 | 4532 | 0.140 |
Why?
|
| PUVA Therapy | 1 | 2015 | 34 | 0.130 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 72 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 1033 | 0.130 |
Why?
|
| Adult | 13 | 2024 | 77950 | 0.130 |
Why?
|
| Melanoma | 3 | 2021 | 5317 | 0.130 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2015 | 116 | 0.130 |
Why?
|
| Quinolinium Compounds | 1 | 2014 | 4 | 0.120 |
Why?
|
| Nails | 1 | 2014 | 36 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2017 | 279 | 0.120 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 21 | 0.120 |
Why?
|
| Aminoquinolines | 1 | 2014 | 46 | 0.120 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2014 | 33 | 0.120 |
Why?
|
| Interferons | 1 | 2015 | 291 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 78 | 0.120 |
Why?
|
| Male | 17 | 2022 | 123000 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2015 | 204 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 235 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2014 | 261 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 980 | 0.110 |
Why?
|
| Female | 16 | 2022 | 141928 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 1249 | 0.110 |
Why?
|
| Hydrochlorothiazide | 1 | 2012 | 61 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2018 | 717 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1350 | 0.100 |
Why?
|
| Middle Aged | 14 | 2022 | 86204 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.100 |
Why?
|
| Monocytes | 1 | 2015 | 788 | 0.100 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 14289 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 7548 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 395 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 29902 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2024 | 1048 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1866 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2022 | 37905 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 4367 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 335 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 15862 | 0.060 |
Why?
|
| Ribavirin | 1 | 2006 | 178 | 0.060 |
Why?
|
| Urate Oxidase | 1 | 2005 | 32 | 0.060 |
Why?
|
| Bilirubin | 1 | 2006 | 221 | 0.060 |
Why?
|
| Hyperuricemia | 1 | 2005 | 34 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2005 | 69 | 0.060 |
Why?
|
| Glia Maturation Factor | 1 | 2024 | 8 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 37 | 0.060 |
Why?
|
| Phosphates | 1 | 2005 | 187 | 0.060 |
Why?
|
| Serotonin Syndrome | 1 | 2003 | 3 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3343 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8865 | 0.060 |
Why?
|
| Hyperkalemia | 1 | 2005 | 79 | 0.060 |
Why?
|
| Oxazolidinones | 1 | 2003 | 60 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2024 | 32848 | 0.060 |
Why?
|
| Perylene | 1 | 2022 | 5 | 0.060 |
Why?
|
| Ointments | 1 | 2022 | 27 | 0.060 |
Why?
|
| Anthracenes | 1 | 2022 | 48 | 0.050 |
Why?
|
| Acetamides | 1 | 2003 | 113 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 71 | 0.050 |
Why?
|
| Inclusion Bodies | 1 | 2022 | 76 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1382 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 2 | 2006 | 1581 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 10331 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2021 | 58 | 0.050 |
Why?
|
| Receptors, CCR4 | 1 | 2020 | 34 | 0.050 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2020 | 19 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2021 | 166 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 21445 | 0.040 |
Why?
|
| Neoplasms | 3 | 2021 | 15193 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 446 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 778 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 87 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1360 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 624 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2024 | 2450 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1429 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2021 | 710 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 1022 | 0.040 |
Why?
|
| Incidence | 2 | 2021 | 5673 | 0.040 |
Why?
|
| Liver | 1 | 2006 | 2961 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2020 | 1681 | 0.030 |
Why?
|
| Psychometrics | 1 | 2020 | 937 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 6915 | 0.030 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.030 |
Why?
|
| Time Factors | 2 | 2020 | 12926 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 799 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 10035 | 0.030 |
Why?
|
| Piperidines | 1 | 2019 | 1035 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2020 | 3033 | 0.030 |
Why?
|
| Risk Factors | 2 | 2010 | 17523 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4892 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2014 | 351 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 15694 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1084 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 4758 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 477 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 531 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 3869 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 5687 | 0.020 |
Why?
|
| Methotrexate | 1 | 2010 | 999 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 329 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 384 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 173 | 0.020 |
Why?
|
| Aerosols | 1 | 2006 | 158 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 31252 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2139 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 13658 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 16273 | 0.010 |
Why?
|
| Linezolid | 1 | 2003 | 64 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 3005 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 544 | 0.010 |
Why?
|
| Child | 1 | 2020 | 29154 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2006 | 1230 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 2315 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 12873 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 11538 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 2638 | 0.010 |
Why?
|